Processa Pharmaceuticals Inc (PCSA) - Net Assets
Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) has net assets worth $5.58 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.81 Million) and total liabilities ($2.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Processa Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.58 Million |
| % of Total Assets | 71.38% |
| Annual Growth Rate | 5.11% |
| 5-Year Change | -78.12% |
| 10-Year Change | N/A |
| Growth Volatility | 703.33 |
Processa Pharmaceuticals Inc - Net Assets Trend (2011–2025)
This chart illustrates how Processa Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore PCSA asset base for the complete picture of this company's asset base.
Annual Net Assets for Processa Pharmaceuticals Inc (2011–2025)
The table below shows the annual net assets of Processa Pharmaceuticals Inc from 2011 to 2025. For live valuation and market cap data, see PCSA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.58 Million | +228.82% |
| 2024-12-31 | $1.70 Million | -66.00% |
| 2023-12-31 | $4.99 Million | -33.22% |
| 2022-12-31 | $7.47 Million | -70.69% |
| 2021-12-31 | $25.49 Million | +11.10% |
| 2020-12-31 | $22.94 Million | +186.29% |
| 2019-12-31 | $8.01 Million | -17.41% |
| 2018-12-31 | $9.70 Million | +2499.67% |
| 2017-12-31 | $373.16K | +118.86% |
| 2016-12-31 | $-1.98 Million | 0.00% |
| 2015-12-31 | $-1.98 Million | -263.82% |
| 2014-12-31 | $1.21 Million | -27.71% |
| 2013-12-31 | $1.67 Million | -34.79% |
| 2012-12-31 | $2.56 Million | -7.67% |
| 2011-12-31 | $2.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Processa Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10078303300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $257.00 | 0.00% |
| Other Components | $106.36 Million | 1907.01% |
| Total Equity | $5.58 Million | 100.00% |
Processa Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Processa Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kerlink SAS
PA:ALKLK
|
$6.78 Million |
|
Watta Holding Bhd
KLSE:7226
|
$6.79 Million |
|
TNF Pharmaceuticals, Inc.
NASDAQ:TNFA
|
$6.80 Million |
|
Nexcom AS
CO:NEXCOM
|
$6.80 Million |
|
Box Pak (Malaysia) Bhd
KLSE:6297
|
$6.78 Million |
|
Creative Medical Technology Holdings Inc
NASDAQ:CELZ
|
$6.78 Million |
|
Openn Negotiation Ltd
AU:OPN
|
$6.78 Million |
|
SMIS Corporation Bhd
KLSE:7132
|
$6.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Processa Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,696,171 to 5,577,314, a change of 3,881,143 (228.8%).
- Net loss of 13,563,834 reduced equity.
- Share repurchases of 10,404 reduced equity.
- New share issuances of 16,597,831 increased equity.
- Other factors increased equity by 857,550.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.56 Million | -243.2% |
| Share Repurchases | $10.40K | -0.19% |
| Share Issuances | $16.60 Million | +297.6% |
| Other Changes | $857.55K | +15.38% |
| Total Change | $- | 228.82% |
Book Value vs Market Value Analysis
This analysis compares Processa Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.60x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.04x to 0.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $62.50 | $2.55 | x |
| 2011-12-31 | $24776.94 | $2.55 | x |
| 2012-12-31 | $6373.89 | $2.55 | x |
| 2013-12-31 | $325.07 | $2.55 | x |
| 2014-12-31 | $133.65 | $2.55 | x |
| 2015-12-31 | $-8.80 | $2.55 | x |
| 2016-12-31 | $-176.10 | $2.55 | x |
| 2017-12-31 | $40.07 | $2.55 | x |
| 2018-12-31 | $909.70 | $2.55 | x |
| 2019-12-31 | $725.05 | $2.55 | x |
| 2020-12-31 | $1529.40 | $2.55 | x |
| 2021-12-31 | $831.79 | $2.55 | x |
| 2022-12-31 | $231.87 | $2.55 | x |
| 2023-12-31 | $95.10 | $2.55 | x |
| 2024-12-31 | $13.86 | $2.55 | x |
| 2025-12-31 | $4.26 | $2.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Processa Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -243.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-243.20%) is below the historical average (-232.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -800.00% | -114.29% | 7.00x | 1.00x | $-162.00K |
| 2011 | -33.87% | -4700.00% | 0.00x | 1.91x | $-1.22 Million |
| 2012 | -95.25% | -1270.15% | 0.05x | 1.52x | $-2.70 Million |
| 2013 | -183.66% | -982.05% | 0.11x | 1.76x | $-3.24 Million |
| 2014 | -374.71% | -2260.85% | 0.08x | 2.10x | $-4.65 Million |
| 2015 | 0.00% | -2957.22% | 1.09x | 0.00x | $-3.16 Million |
| 2016 | 0.00% | -2957.22% | 1.09x | 0.00x | $-3.16 Million |
| 2017 | -497.45% | -37126.30% | 0.00x | 7.99x | $-1.89 Million |
| 2018 | -38.81% | 0.00% | 0.00x | 1.36x | $-4.74 Million |
| 2019 | -41.91% | 0.00% | 0.00x | 1.36x | $-4.16 Million |
| 2020 | -83.00% | 0.00% | 0.00x | 1.10x | $-21.33 Million |
| 2021 | -44.84% | 0.00% | 0.00x | 1.04x | $-13.98 Million |
| 2022 | -367.09% | 0.00% | 0.00x | 1.15x | $-28.17 Million |
| 2023 | -222.91% | 0.00% | 0.00x | 1.16x | $-11.62 Million |
| 2024 | -698.64% | 0.00% | 0.00x | 1.90x | $-12.02 Million |
| 2025 | -243.20% | 0.00% | 0.00x | 1.40x | $-14.12 Million |
Industry Comparison
This section compares Processa Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Processa Pharmaceuticals Inc (PCSA) | $5.58 Million | -800.00% | 0.40x | $6.78 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer ce… Read more